Biotech Values

[genisi]

The rapid onset of resistance is a feature of HCV protease inhibitors in general, not just Telaprevir. These drugs clearly can't be used as monotherapy.

HCV RNA replication is a highly error prone process with rapid viral production rate to begin with. This gives rise to high mutation rate and makes the emergence of resistant populations under drug selection pressure a significant issue. In order to reduce or eliminate drug resistance, combos aiming at several targets are of course a better strategy than a sole drug even one with a high barrier to resistance.